C
인트론바이오
048530KOSDAQ49.0 / 100
Reference Date: 2026-10-23
Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 9.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
IntronBio focuses on developing biopharmaceuticals based on bacteriophage technology and molecular diagnostic solutions. The company's drug development division targets antibiotic-resistant bacterial infections and immune therapies, while its diagnostic division produces molecular test kits, including COVID-19 diagnostic products, contributing to revenue.
Number of Employees
77people
Average Salary
64.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.40Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
-11.66Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
0.52Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼21.8% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼55.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -8.0% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (19%, downtrend)
Current 3,165Won52-week high 6,65052-week low 2,330
1-month return5.0Point
1m +9.14% (rising)
Volume trend6.0Point
Volume surge
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0